These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14652793)

  • 21. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI relapses have significant pathologic and clinical implications in multiple sclerosis.
    Traboulsee A
    J Neurol Sci; 2007 May; 256 Suppl 1():S19-22. PubMed ID: 17346748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis.
    Andrews HE; Nichols PP; Bates D; Turnbull DM
    Med Hypotheses; 2005; 64(4):669-77. PubMed ID: 15694681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Axonal damage in multiple sclerosis].
    Bartosik-Psujek H; Stelmasiak Z
    Neurol Neurochir Pol; 2002; 36(3):505-12. PubMed ID: 12185807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathophysiology of multiple sclerosis].
    Smith KJ
    Rev Prat; 2006 Jun; 56(12):1299-303. PubMed ID: 16948217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice.
    Linker RA; Sendtner M; Gold R
    J Neurol Sci; 2005 Jun; 233(1-2):167-72. PubMed ID: 15949503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.
    Hauser SL; Oksenberg JR
    Neuron; 2006 Oct; 52(1):61-76. PubMed ID: 17015227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of axonal and neuronal damage in multiple sclerosis.
    Dutta R; Trapp BD
    Neurology; 2007 May; 68(22 Suppl 3):S22-31; discussion S43-54. PubMed ID: 17548565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cortical demyelination and diffuse white matter injury in multiple sclerosis.
    Kutzelnigg A; Lucchinetti CF; Stadelmann C; Brück W; Rauschka H; Bergmann M; Schmidbauer M; Parisi JE; Lassmann H
    Brain; 2005 Nov; 128(Pt 11):2705-12. PubMed ID: 16230320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.
    Zaveri MS; Conger A; Salter A; Frohman TC; Galetta SL; Markowitz CE; Jacobs DA; Cutter GR; Ying GS; Maguire MG; Calabresi PA; Balcer LJ; Frohman EM
    Arch Neurol; 2008 Jul; 65(7):924-8. PubMed ID: 18625859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.
    Calabrese M; De Stefano N; Atzori M; Bernardi V; Mattisi I; Barachino L; Morra A; Rinaldi L; Romualdi C; Perini P; Battistin L; Gallo P
    Arch Neurol; 2007 Oct; 64(10):1416-22. PubMed ID: 17923625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of thalamic gray matter loss in pediatric multiple sclerosis.
    Mesaros S; Rocca MA; Absinta M; Ghezzi A; Milani N; Moiola L; Veggiotti P; Comi G; Filippi M
    Neurology; 2008 Mar; 70(13 Pt 2):1107-12. PubMed ID: 18272867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.
    Bjartmar C; Wujek JR; Trapp BD
    J Neurol Sci; 2003 Feb; 206(2):165-71. PubMed ID: 12559505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axonal damage in multiple sclerosis: a complex issue in a complex disease.
    Grigoriadis N; Ben-Hur T; Karussis D; Milonas I
    Clin Neurol Neurosurg; 2004 Jun; 106(3):211-7. PubMed ID: 15177770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drug therapies for multiple sclerosis.
    Mangas A; Coveñas R; Geffard M
    Curr Opin Neurol; 2010 Jun; 23(3):287-92. PubMed ID: 20414110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis.
    Wang D; Ayers MM; Catmull DV; Hazelwood LJ; Bernard CC; Orian JM
    Glia; 2005 Aug; 51(3):235-40. PubMed ID: 15812814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage.
    Owens T
    Curr Opin Neurol; 2003 Jun; 16(3):259-65. PubMed ID: 12858060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.